Hyeoung Joon Kim


Ontology type: schema:Person     


Person Info

NAME

Hyeoung Joon

SURNAME

Kim

Publications in SciGraph latest 50 shown

  • 2019-12 Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma in BMC CANCER
  • 2019-01 18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2018-12-16 HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia in LEUKEMIA
  • 2018-12 Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL) in BMC CANCER
  • 2018-12 Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts in ANNALS OF HEMATOLOGY
  • 2018-06 Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients in ANNALS OF HEMATOLOGY
  • 2017-01 HBV reactivation risk factors in patients with chronic HBV infection with low replicative state and resolved HBV infection undergoing hematopoietic stem cell transplantation in Korea in HEPATOLOGY INTERNATIONAL
  • 2016-12 Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen in BMC CANCER
  • 2016-12 Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia in JOURNAL OF TRANSLATIONAL MEDICINE
  • 2016-11 Report on outcomes of hypomethylating therapy for analyzing prognostic value of Revised International Prognostic Scoring System for patients with lower-risk myelodysplastic syndromes in ANNALS OF HEMATOLOGY
  • 2016-10 Thalidomide-based induction regimens are as effective as bortezomib-based regimens in elderly patients with multiple myeloma with cereblon expression in ANNALS OF HEMATOLOGY
  • 2016-09 Naïve CD8+ T cell derived tumor-specific cytotoxic effectors as a potential remedy for overcoming TGF-β immunosuppression in the tumor microenvironment in SCIENTIFIC REPORTS
  • 2016-08 Sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2) reduces the migratory capacity of CCL21-treated monocyte-derived dendritic cells in EXPERIMENTAL & MOLECULAR MEDICINE
  • 2016-03 Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML in ANNALS OF HEMATOLOGY
  • 2016-01 Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant in ANNALS OF HEMATOLOGY
  • 2016-01 Erratum to: Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant in ANNALS OF HEMATOLOGY
  • 2016-01 Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen in ANNALS OF HEMATOLOGY
  • 2015-12 Prognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma in BMC CANCER
  • 2015-10 A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2014-11 Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2014-05 Decreased body mass index is associated with poor prognosis in patients with multiple myeloma in ANNALS OF HEMATOLOGY
  • 2014-02 Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia in NATURE
  • 2013-06 IL10 and TNF variants and risk of non-Hodgkin lymphoma among three Asian populations in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2013-06 Autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide as an intensifying frontline treatment in patients with peripheral T cell lymphomas: a multicenter retrospective trial in ANNALS OF HEMATOLOGY
  • 2013-04 Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment in ANNALS OF HEMATOLOGY
  • 2013-04 Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era in ANNALS OF HEMATOLOGY
  • 2013-03 Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2013-02 KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement in ANNALS OF HEMATOLOGY
  • 2013-01 Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2012-09 Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • 2012-07 A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma in ANNALS OF HEMATOLOGY
  • 2012-06 Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients in MEDICAL ONCOLOGY
  • 2012-03 Identification of novel HLA-A*0201-restricted epitopes from anterior gradient-2 as a tumor-associated antigen against colorectal cancer in CELLULAR & MOLECULAR IMMUNOLOGY
  • 2012-01 Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy in CELLULAR & MOLECULAR IMMUNOLOGY
  • 2012-01 A critical step for JNK activation: isomerization by the prolyl isomerase Pin1 in CELL DEATH & DIFFERENTIATION
  • 2012 In vitro induction of anterior gradient-2-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses as a potential therapy for colorectal cancer in EXPERIMENTAL & MOLECULAR MEDICINE
  • 2011-12 Successful cross-presentation of allogeneic myeloma cells by autologous alpha-type 1-polarized dendritic cells as an effective tumor antigen in myeloma patients with matched monoclonal immunoglobulins in ANNALS OF HEMATOLOGY
  • 2011-11 Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after imatinib therapy in chronic myeloid leukemia in ANNALS OF HEMATOLOGY
  • 2011-07 Type I and II interferons enhance dendritic cell maturation and migration capacity by regulating CD38 and CD74 that have synergistic effects with TLR agonists in CELLULAR & MOLECULAR IMMUNOLOGY
  • 2010-12 PARP-1 Val762Ala polymorphism is associated with reduced risk of non-Hodgkin lymphoma in Korean males in BMC MEDICAL GENETICS
  • 2010-08 Comparative analysis of outcomes of allogeneic peripheral blood stem cell transplantation from related and unrelated donors in ANNALS OF HEMATOLOGY
  • 2010-08 Alpha-type 1-polarized dendritic cells loaded with apoptotic allogeneic myeloma cell line induce strong CTL responses against autologous myeloma cells in ANNALS OF HEMATOLOGY
  • 2010-08 Positive regulation of apoptosis signal-regulating kinase 1 by dual-specificity phosphatase 13A in CELLULAR AND MOLECULAR LIFE SCIENCES
  • 2010-07 Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib in ANNALS OF HEMATOLOGY
  • 2010-05 Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study in ANNALS OF HEMATOLOGY
  • 2010 Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist in EXPERIMENTAL & MOLECULAR MEDICINE
  • 2010 Change in serum proteome during allogeneic hematopoietic stem cell transplantation and clinical significance of serum C-reactive protein and haptoglobin in EXPERIMENTAL & MOLECULAR MEDICINE
  • 2010-01 Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine in ANNALS OF HEMATOLOGY
  • 2009-11 Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens in ANNALS OF HEMATOLOGY
  • 2009-07 Polymyositis and myocarditis after donor lymphocyte infusion in INTERNATIONAL JOURNAL OF HEMATOLOGY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.411602.0", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412311.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411087.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.267335.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.452901.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.419971.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.170205.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.7445.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.189967.8", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.65499.37", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411162.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.14005.30", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.222754.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.240145.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.489770.5", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.22937.3d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410567.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411947.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.7700.0", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.413734.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.416628.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411597.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415224.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.1010.0", 
            "type": "Organization"
          }
        ], 
        "familyName": "Kim", 
        "givenName": "Hyeoung Joon", 
        "id": "sg:person.0617770714.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617770714.19"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T15:02", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_732.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.0617770714.19'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.0617770714.19'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.0617770714.19'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.0617770714.19'


     

    This table displays all metadata directly associated to this object as RDF triples.

    62 TRIPLES      10 PREDICATES      34 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.0617770714.19 schema:affiliation Nb498d490fa8d466194b2216c124c108a
    2 https://www.grid.ac/institutes/grid.1010.0
    3 https://www.grid.ac/institutes/grid.14005.30
    4 https://www.grid.ac/institutes/grid.170205.1
    5 https://www.grid.ac/institutes/grid.189967.8
    6 https://www.grid.ac/institutes/grid.222754.4
    7 https://www.grid.ac/institutes/grid.22937.3d
    8 https://www.grid.ac/institutes/grid.240145.6
    9 https://www.grid.ac/institutes/grid.267335.6
    10 https://www.grid.ac/institutes/grid.410567.1
    11 https://www.grid.ac/institutes/grid.411087.b
    12 https://www.grid.ac/institutes/grid.411162.1
    13 https://www.grid.ac/institutes/grid.411597.f
    14 https://www.grid.ac/institutes/grid.411947.e
    15 https://www.grid.ac/institutes/grid.412311.4
    16 https://www.grid.ac/institutes/grid.413734.6
    17 https://www.grid.ac/institutes/grid.415224.4
    18 https://www.grid.ac/institutes/grid.416628.f
    19 https://www.grid.ac/institutes/grid.419971.3
    20 https://www.grid.ac/institutes/grid.452901.b
    21 https://www.grid.ac/institutes/grid.489770.5
    22 https://www.grid.ac/institutes/grid.65499.37
    23 https://www.grid.ac/institutes/grid.7445.2
    24 https://www.grid.ac/institutes/grid.7700.0
    25 schema:familyName Kim
    26 schema:givenName Hyeoung Joon
    27 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0617770714.19
    28 schema:sdDatePublished 2019-03-07T15:02
    29 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    30 schema:sdPublisher N29a0450532e647f388e1f11c06f28387
    31 sgo:license sg:explorer/license/
    32 sgo:sdDataset persons
    33 rdf:type schema:Person
    34 N29a0450532e647f388e1f11c06f28387 schema:name Springer Nature - SN SciGraph project
    35 rdf:type schema:Organization
    36 Nb498d490fa8d466194b2216c124c108a schema:affiliation https://www.grid.ac/institutes/grid.411602.0
    37 sgo:isCurrent true
    38 rdf:type schema:OrganizationRole
    39 https://www.grid.ac/institutes/grid.1010.0 schema:Organization
    40 https://www.grid.ac/institutes/grid.14005.30 schema:Organization
    41 https://www.grid.ac/institutes/grid.170205.1 schema:Organization
    42 https://www.grid.ac/institutes/grid.189967.8 schema:Organization
    43 https://www.grid.ac/institutes/grid.222754.4 schema:Organization
    44 https://www.grid.ac/institutes/grid.22937.3d schema:Organization
    45 https://www.grid.ac/institutes/grid.240145.6 schema:Organization
    46 https://www.grid.ac/institutes/grid.267335.6 schema:Organization
    47 https://www.grid.ac/institutes/grid.410567.1 schema:Organization
    48 https://www.grid.ac/institutes/grid.411087.b schema:Organization
    49 https://www.grid.ac/institutes/grid.411162.1 schema:Organization
    50 https://www.grid.ac/institutes/grid.411597.f schema:Organization
    51 https://www.grid.ac/institutes/grid.411602.0 schema:Organization
    52 https://www.grid.ac/institutes/grid.411947.e schema:Organization
    53 https://www.grid.ac/institutes/grid.412311.4 schema:Organization
    54 https://www.grid.ac/institutes/grid.413734.6 schema:Organization
    55 https://www.grid.ac/institutes/grid.415224.4 schema:Organization
    56 https://www.grid.ac/institutes/grid.416628.f schema:Organization
    57 https://www.grid.ac/institutes/grid.419971.3 schema:Organization
    58 https://www.grid.ac/institutes/grid.452901.b schema:Organization
    59 https://www.grid.ac/institutes/grid.489770.5 schema:Organization
    60 https://www.grid.ac/institutes/grid.65499.37 schema:Organization
    61 https://www.grid.ac/institutes/grid.7445.2 schema:Organization
    62 https://www.grid.ac/institutes/grid.7700.0 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...